[go: up one dir, main page]

WO2005115397A3 - Compositions et traitements pour moduler une kinase et/ou une hmg-coa reductase - Google Patents

Compositions et traitements pour moduler une kinase et/ou une hmg-coa reductase Download PDF

Info

Publication number
WO2005115397A3
WO2005115397A3 PCT/US2005/014833 US2005014833W WO2005115397A3 WO 2005115397 A3 WO2005115397 A3 WO 2005115397A3 US 2005014833 W US2005014833 W US 2005014833W WO 2005115397 A3 WO2005115397 A3 WO 2005115397A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
compositions
treatments
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014833
Other languages
English (en)
Other versions
WO2005115397A2 (fr
Inventor
John Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmix Corp
Original Assignee
Pharmix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmix Corp filed Critical Pharmix Corp
Publication of WO2005115397A2 publication Critical patent/WO2005115397A2/fr
Publication of WO2005115397A3 publication Critical patent/WO2005115397A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des compositions de matière, des nécessaires et leurs méthodes d'utilisation dans le traitement d'états liés à la kinase et/ou d'états liés à la HMG-CoA réductase. L'invention concerne en particulier des compositions destinées au traitement d'états cardiovasculaires et/ou immunocompromis chez un animal par modulation d'une ou de plusieurs MAP kinases et/ou d'une HMG-CoA réductase, ainsi que des formulations et des modes d'administration desdites compositions. L'invention concerne également des procédés de conception rationnelle de modulateurs de MAP kinases, de HMG-CoA réductase, ou des deux, destinés à être utilisés dans la mise en oeuvre de la présente invention.
PCT/US2005/014833 2004-04-29 2005-04-29 Compositions et traitements pour moduler une kinase et/ou une hmg-coa reductase Ceased WO2005115397A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56711804P 2004-04-29 2004-04-29
US60/567,118 2004-04-29
US63068404P 2004-11-23 2004-11-23
US63068304P 2004-11-23 2004-11-23
US60/630,684 2004-11-23
US60/630,683 2004-11-23

Publications (2)

Publication Number Publication Date
WO2005115397A2 WO2005115397A2 (fr) 2005-12-08
WO2005115397A3 true WO2005115397A3 (fr) 2006-07-13

Family

ID=35451387

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/014833 Ceased WO2005115397A2 (fr) 2004-04-29 2005-04-29 Compositions et traitements pour moduler une kinase et/ou une hmg-coa reductase
PCT/US2005/014843 Ceased WO2006028524A2 (fr) 2004-04-29 2005-04-29 Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014843 Ceased WO2006028524A2 (fr) 2004-04-29 2005-04-29 Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase

Country Status (3)

Country Link
EP (1) EP1755607A2 (fr)
JP (1) JP2007535558A (fr)
WO (2) WO2005115397A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329703B2 (en) 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
EP1948168A4 (fr) * 2005-10-28 2010-10-06 Numerate Inc Compositions et traitements destines a inhiber kinase et/ou hmg-coa reductase
JP2010506843A (ja) 2006-10-13 2010-03-04 エックスティーエル バイオファーマシューティカルズ リミテッド Ｈｃｖを治療するための化合物および方法
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
EP2350049B1 (fr) 2008-10-02 2014-02-26 Respivert Limited Inhibiteurs de la p38 map kinase
NZ593104A (en) 2008-12-11 2012-11-30 Respivert Ltd P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2308866A1 (fr) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles et leur utilisation comme fongicides
HUE059041T2 (hu) * 2013-10-17 2022-10-28 Blueprint Medicines Corp Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
WO2018183712A1 (fr) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Composés de pyrrolo[1,2-b]pyridazine et compositions utiles pour traiter des troubles liés à kit et pdgfr
CA3136802A1 (fr) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Derives de pyrrolotriazine pour le traitement de maladies mediees par kit et pdgfra
SMT202300447T1 (it) 2019-04-12 2024-01-10 Blueprint Medicines Corp Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177121B1 (en) * 1997-09-29 2001-01-23 Purdue Research Foundation Composition and method for producing low cholesterol eggs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237470B (it) * 1988-10-03 1993-06-07 Glaxo Group Ltd Derivati di imidazolo, procedimenti per produrli e composizioni farmaceutiche che li contengono

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177121B1 (en) * 1997-09-29 2001-01-23 Purdue Research Foundation Composition and method for producing low cholesterol eggs

Also Published As

Publication number Publication date
JP2007535558A (ja) 2007-12-06
WO2006028524A2 (fr) 2006-03-16
EP1755607A2 (fr) 2007-02-28
WO2005115397A2 (fr) 2005-12-08
WO2006028524A3 (fr) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2007051065A3 (fr) Compositions et traitements destines a inhiber kinase et/ou hmg-coa reductase
WO2005107747A3 (fr) Preparations de diindolymethane destinee de traitement de leiomyomes
WO2007011962A3 (fr) Traitement du cancer
WO2008046003A3 (fr) Inhibiteurs de kinase utiles pour le traitement de maladies myéloproliférantes et d'autres maladies proliférantes
TW200801008A (en) Protein kinase inhibitors
WO2010006086A3 (fr) Inhibiteurs de kinases et procédés d'utilisation
WO2010009342A3 (fr) Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
WO2007013950A3 (fr) Polytherapie de tumeurs exprimant her
WO2006078287A3 (fr) Inhibiteurs de pde4b
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2005116025A3 (fr) Composes
WO2007149287A3 (fr) Compositions de facteur de transfert et méthodes
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2005048948A3 (fr) Derives d'uree en tant que modulateurs de la kinase
WO2005094376A3 (fr) Methodes et compositions synergetiques utilisees dans le traitement du cancer
EP2532657A3 (fr) Composés et procédés d'utilisation
WO2006029183A3 (fr) Compositions et procedes pour le diagnostic et le traitement d'une tumeur
WO2007067781A3 (fr) Inhibiteurs de proteines kinases
DE602006014848D1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhän
WO2005037259A3 (fr) Procedes et compositions de prevention ou de traitement de neoplasie comprenant un inhibiteur de la cox-2 en combinaison avec un antagoniste recepteur du facteur de croissance epidermale
WO2005077954A3 (fr) Nouvelles pyrazolopyrimidines tenant lieu d'inhibiteurs de la kinase dependant de la cycline
WO2008083367A3 (fr) Triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs de axl
WO2007111904A3 (fr) Inhibiteurs de la c-met proteine kinase
WO2007058942A3 (fr) Imidazopyrazines inhibant la proteine kinase
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase